

Title (en)
METHOD FOR PREDICTING THE RESPONSE TO AN ANTI-HER2 CONTAINING THERAPY AND/OR CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER

Title (de)
VERFAHREN ZUR VORHERSAGE DER REAKTION AUF EINE THERAPIE MIT ANTI-HER2 UND/ODER CHEMOTHERAPIE BEI PATIENTEN MIT BRUSTKREBS

Title (fr)
PROCÉDÉ PERMETTANT DE PRÉDIRE LA RÉPONSE À UNE THÉRAPIE ET/OU UNE CHIMIOTHÉRAPIE À BASE D'ANTI-HER2 CHEZ DES PATIENTES ATTEINTES D'UN CANCER DU SEIN

Publication
EP 3102697 A1 20161214 (EN)

Application
EP 15702464 A 20150202

Priority
• EP 14153692 A 20140203
• EP 14153786 A 20140204
• EP 2015052081 W 20150202

Abstract (en)
[origin: WO2015114146A1] A method for predicting a response and/or survival after anti-HER2 containing therapy and/or chemotherapy in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprises the determination of the expression level of at least one of the following 12 genes: CCLS, CD21, CD80, CDBA, CTLA4, CXCL13, CXCL9, FOXP3, ID01, IGKC, PD1, PDL1 in a tumor sample from said patient, wherein said expression levels indicate a) the likelihood of benefit from inclusion of Carboplatin in a chemotherapy regimen; b) the likelihood of response to chemotherapy; c) the likelihood that the tumor is infiltrated with leucocytes; d) the likelihood of benefit from anti-HER2 containing therapy; e) the likelihood of developing metastases after treatment.

IPC 8 full level
C12Q 1/68 (2006.01)

CPC (source: EP)
C12Q 1/6886 (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/158** (2013.01)

Citation (search report)
See references of WO 2015114146A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2015114146 A1 20150806; EP 3102697 A1 20161214

DOCDB simple family (application)
EP 2015052081 W 20150202; EP 15702464 A 20150202